Collapsed man saved from rolling into Ladybower Reservoir
Derbyshire Fire and Rescue Service, Derbyshire Police, East Midlands Ambulance Service and the MRT attended the scene, with fire crews able to reach the casualty and help them back up the bankside to safety.A spokesperson for Edale EMT said it was an "efficient multi-agency response" which led to a "speedy conclusion"."Fortunately, there were no injuries sustained by the casualty or friend, and a team doctor passed them both fit to return to the car park in a Severn Trent Ranger service vehicle for their return journey home."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
BBC News
5 days ago
- BBC News
Helicopter rescue for walker injured in fall in Peak District
A injured walker was airlifted to safety after falling while hiking in the Peak rescue volunteers were called to Grindsbrook, near Kinder Scout, at 13:38 BST on Tuesday after a report the casualty had suffered a "painful" ankle injury and was unable to Mountain Rescue Team said a volunteer team member had been running nearby and was able to reach the scene and help.A coastguard helicopter was called as other volunteers made their way there. The helicopter took the walker to a nearby cement works, where a waiting ambulance took the casualty to hospital in Sheffield.
Reuters
29-07-2025
- Reuters
AstraZeneca seeks US drug price cuts amid expansion plans, strong demand
July 29 (Reuters) - AstraZeneca (AZN.L), opens new tab has proposed price cuts to its drugs in the United States, its CEO said on Tuesday, days after unveiling a $50 billion investment to expand there, as President Donald Trump pressures pharmaceuticals companies to lower costs. Speaking to journalists after second-quarter revenue and profit beat expectations, CEO Pascal Soriot said Trump's administration was reviewing the company's proposals. He did not specify which drugs were included. Trump has repeatedly threatened tariffs as he also pushes drugmakers to reduce prices to what other countries pay. However, he signalled earlier this month that companies would be given a year to 18 months to "get their act together" before any sector-specific levies take effect. "We definitely support the idea of rebalancing with some reduction of pricing levels in the U.S., and some increase, we're not talking about massive increases, in Europe," AstraZeneca's Soriot said. He added he expects all medicines for U.S. patients to be produced locally within a few months, and is also considering selling some medicines to customers directly. AstraZeneca shares rose as much as 3% after its results, but pared some gains to trade up 1.6% by 1214 GMT. "The big uncertainty, unsurprisingly, remains U.S. tariffs and Most Favoured Nation pricing in the pharmaceutical sector. AstraZeneca has looked to get ahead of this uncertainty," said Sheena Berry, a healthcare analyst at Quilter Cheviot. The U.S. accounted for more than 40% of AstraZeneca's revenue in 2024. The UK's largest-listed company by market value had prioritised the U.S. market - the world's largest, worth $635 billion - even before Trump's return to office. AstraZeneca's efforts are paying off as strong U.S. demand, and robust sales of newer cancer, heart and kidney disease medicines drove total revenue for the second quarter 11% higher to $14.46 billion, on a constant currency basis. It logged double-digit growth in the U.S. despite headwinds from changes in U.S. Medicare price negotiations, while sales of cancer drugs including Tagrisso, Lynparza, Calquence, Truqap and Imfinzi beat expectations. Core earnings stood at $2.17 per share. Analysts were expecting $2.16, from $14.15 billion in sales, according to a company-provided consensus. AstraZeneca is betting on a wave of expected launches of 20 new medicines and its U.S. expansion to reach $80 billion in annual revenue by 2030 and offset generic competition. On Tuesday, it maintained its 2025 outlook and increased its interim dividend by 3%. The drugmaker in April forecast only a limited impact from potential U.S. tariffs, adding it would be able to meet its annual outlook if the levies on European imports were similar to those in other industries. A European Union-U.S. trade deal over the weekend will result in a 15% tariff on most goods, including pharmaceuticals, from the region.
Reuters
29-07-2025
- Reuters
Obesity drugmaker Novo Nordisk picks Maziar Mike Doustdar as new CEO, shares plunge
COPENHAGEN, July 29 (Reuters) - Novo Nordisk named Maziar Mike Doustdar as its new chief executive on Tuesday, relying on an experienced company insider to revive sales and a share price hit by worries the maker of weight-loss drug Wegovy is falling behind in a race it started. The appointment comes after the abrupt removal in May of CEO Lars Fruergaard Jorgensen by Novo ( opens new tab and the Novo Nordisk Foundation - the Danish company's controlling shareholder, and follows a growth warning earlier on Tuesday. Shares in Novo Nordisk were down by around 16% following the profit warning and plummeted further following the CEO announcement. Shares were down by as much as 29.8% by 1149 GMT, wiping over 80 billion euros ($92.26 billion) off its market value, though later recovered some ground to be down 20%. Doustdar, an Iranian-born, Austrian national, who grew up in the United States, joined Novo in 1992 and will take on the new role on August 7. Doustdar currently serves as vice president for international operations, a role he took after leading the company's businesses first in the Middle East and then in Southeast Asia, Novo said. Some analysts and investors had argued that Novo should select an American, or a person with extensive experience working in the United States as its next CEO. Novo has lost its first-mover advantage in the United States this year to U.S. rival Eli Lilly (LLY.N), opens new tab. Novo's profit warning came on rising competition and copycat versions of its weight-loss drug that hurt sales this year, but a crackdown on these so-called compounded versions of Wegovy in May could improve the situation. The new chief executive's most urgent challenge, according to investors and analysts, is to revive Novo's performance in the United States, the largest market by far for weight-loss drugs and where they are most profitable. Novo launched its weight-loss drug Wegovy nearly two and a half years before U.S. rival Eli Lilly's Zepbound. But Zepbound prescriptions surpassed those of Wegovy this year by more than 100,000 a week. The appointment comes at a challenging time for the global pharmaceutical industry as U.S. President Donald Trump threatens to impose tariffs on imports and calls on drugmakers to lower their U.S. prescription prices. Jorgensen led Novo through a period of meteoric growth as it led the weight-loss drug boom, becoming Europe's most valuable listed company following the launch of Wegovy in 2021. At its peak in June 2024 Novo was worth as much as $615 billion. But Novo shares have plunged since then on investor concerns about the company's experimental drug pipeline and its ability to navigate challenges in the U.S. market, such as the threat to its sales from compounded copies of Wegovy and Lilly's Zepbound. ($1 = 0.8672 euros)
